Glenmark Pharma launches Sitagliptin and its FDCs for Type 2 diabetes in India
The medicines will be available under the brand name SITAZIT, SITAZIT- M, SITAZIT- M ER and SITAZIT D.
Advertisement
Mumbai: Glenmark Pharmaceuticals Limited, an innovation-driven global pharmaceutical company, has launched sitagliptin and its Fixed Dose Combinations (FDCs), at affordable price for adults with Type 2 diabetes in India. The company has introduced 8 different combinations of sitagliptin based drugs under the brand name SITAZIT and its variants at affordable price.
"Glenmark's SITAZIT and its variants will play an instrumental role in raising accessibility of sitagliptin to type- 2 diabetic patients, which is considered as the gold standard molecule in DPP4 inhibitor therapy. It will help the patients to manage their glycemic level effectively and bring better compliance. These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens," the company stated.
The medicines will be available under the brand name SITAZIT, SITAZIT- M, SITAZIT- M ER and SITAZIT D. Each of these brands will have two different variants – SITAZIT (sitagliptin) will be available in 50 mg and 100 mg variants; SITAZIT M will have sitagliptin (50 mg) + metformin (500 mg/ 1000 mg); SITAZIT M ER will have sitagliptin (100 mg) + metformin SR (500 mg/ 1000 mg). The brand SITAZIT D is a new combination with two variants SITAZIT D 100/10, which will have sitagliptin (100 mg) + dapagliflozin (10 mg) and SITAZIT D 50/5 which will have sitagliptin (50 mg) + dapagliflozin (5 mg).
In 2015, Glenmark has launched its DPP4 inhibitor – teneligliptin at a price that was approximately 55% lower than the other DPP4 inhibitors available in India at that time. Glenmark has also launched its globally researched, innovator molecule remogliflozin in 2019, at a price around 55% lesser than other SGLT2 inhibitors available in the Indian market at that time.
Read also: Glenmark gets one USFDA observation for Aurangabad facility
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.